Allena Pharmaceuticals, Inc. (ALNA)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Allena Pharmaceuticals, Inc. (ALNA). Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Allena Pharmaceuticals, Inc. (ALNA) Healthcare & Pipeline Overview
Allena Pharmaceuticals, Inc. is a biotechnology firm specializing in oral enzyme therapeutics for rare metabolic and kidney disorders, with ALLN-346 as its primary focus. The company operates within the competitive biotechnology sector, addressing unmet needs in chronic kidney disease and related conditions.
Investment Thesis
Allena Pharmaceuticals, Inc. presents a focused investment opportunity within the biotechnology sector, driven by its lead product candidate, ALLN-346, targeting hyperuricemia and gout in advanced chronic kidney disease patients. The potential for ALLN-346 to address a significant unmet need in this patient population is a key value driver. The company's success hinges on positive clinical trial outcomes and subsequent regulatory approval. Key risks include clinical trial failures, regulatory hurdles, and competition from existing and emerging therapies. With a P/E ratio of -0.07 and a beta of 1.15, the company reflects the inherent volatility and speculative nature of biotechnology investments. The absence of a dividend underscores the company's focus on reinvesting earnings into research and development.
Based on FMP financials and quantitative analysis
Key Highlights
- Lead product candidate ALLN-346 targets hyperuricemia and gout in advanced chronic kidney disease patients.
- Focus on oral enzyme therapeutics offers a potentially convenient treatment option.
- Strategic focus on rare and severe diseases allows for targeted patient populations and potential market exclusivity.
- Incorporated in 2011, indicating a relatively young company in the biotechnology space.
- Headquartered in Newton, Massachusetts, a hub for biotechnology and pharmaceutical companies.
Competitors & Peers
Strengths
- Proprietary enzyme technology platform
- Lead product candidate targeting a specific unmet need
- Experienced management team
- Focus on rare and severe diseases
Weaknesses
- Limited financial resources
- Dependence on a single product candidate
- Small number of employees
- Lack of commercial infrastructure
Catalysts
- Upcoming: Clinical trial results for ALLN-346.
- Upcoming: Potential regulatory approval of ALLN-346.
- Ongoing: Strategic partnerships and collaborations.
- Ongoing: Expansion into new therapeutic areas.
Risks
- Potential: Clinical trial failures.
- Potential: Regulatory hurdles.
- Potential: Competition from existing therapies.
- Ongoing: Limited financial resources.
- Ongoing: Dependence on a single product candidate.
Growth Opportunities
- Expansion into New Therapeutic Areas: Allena Pharmaceuticals, Inc. can leverage its expertise in enzyme therapeutics to expand into new therapeutic areas beyond hyperuricemia and gout. This could involve developing novel enzyme-based therapies for other metabolic or kidney disorders with unmet medical needs. The market size for enzyme replacement therapies is projected to reach billions of dollars in the coming years, presenting a significant growth opportunity for Allena. Timeline: 3-5 years.
- Geographic Expansion: Allena Pharmaceuticals, Inc. can expand its geographic reach beyond the United States to target international markets with significant patient populations suffering from hyperuricemia and gout. This could involve establishing partnerships with international distributors or pursuing regulatory approvals in key markets such as Europe and Asia. The global market for gout treatment is expected to grow substantially, driven by increasing prevalence and aging populations. Timeline: 2-4 years.
- Strategic Partnerships and Collaborations: Allena Pharmaceuticals, Inc. can pursue strategic partnerships and collaborations with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its product candidates. This could involve licensing agreements, co-development partnerships, or joint ventures. Collaborations can provide access to additional resources, expertise, and market access. Timeline: Ongoing.
- Development of Next-Generation Enzyme Therapeutics: Allena Pharmaceuticals, Inc. can invest in the development of next-generation enzyme therapeutics with improved efficacy, safety, and delivery methods. This could involve engineering novel enzymes with enhanced catalytic activity or developing innovative oral delivery systems to improve bioavailability. The market for advanced drug delivery technologies is rapidly growing, driven by the need for more effective and convenient therapies. Timeline: 5+ years.
- Acquisition of Complementary Technologies or Companies: Allena Pharmaceuticals, Inc. can pursue strategic acquisitions of complementary technologies or companies to expand its product pipeline and capabilities. This could involve acquiring companies with expertise in enzyme engineering, drug delivery, or related therapeutic areas. Acquisitions can provide access to new technologies, intellectual property, and talent. Timeline: Opportunistic.
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships and collaborations
- Geographic expansion
- Favorable regulatory environment for orphan drugs
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing therapies
- Patent expiration
Competitive Advantages
- Proprietary enzyme technology
- Patent protection for ALLN-346
- Focus on rare and severe diseases
- Specialized expertise in enzyme therapeutics
About ALNA
Allena Pharmaceuticals, Inc., founded in 2011 and headquartered in Newton, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing oral enzyme therapeutics. The company focuses on addressing unmet needs in patients with rare and severe metabolic and kidney disorders. Allena's lead product candidate, ALLN-346, is a novel, orally administered enzyme designed to degrade urate in the gastrointestinal tract. This therapeutic approach aims to reduce the burden of hyperuricemia and gout, particularly in individuals with advanced chronic kidney disease (CKD). The company's research and development efforts are centered on enzyme-based therapies that can be administered orally, offering a convenient and potentially more effective treatment option for patients with these debilitating conditions. Allena's strategic focus on rare and severe diseases allows it to target specific patient populations with significant unmet medical needs, potentially leading to accelerated regulatory pathways and market exclusivity. The company's operations are currently based in the United States, with a focus on clinical development and eventual commercialization of its lead product candidate.
What They Do
- Discovers oral enzyme therapeutics
- Develops oral enzyme therapeutics
- Commercializes oral enzyme therapeutics
- Treats patients with rare metabolic disorders
- Treats patients with severe metabolic disorders
- Treats patients with rare kidney disorders
- Treats patients with severe kidney disorders
Business Model
- Develops and patents novel enzyme therapeutics.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from the FDA.
- Commercializes approved products through sales and marketing efforts.
Industry Context
Allena Pharmaceuticals, Inc. operates within the biotechnology industry, a sector characterized by high innovation, significant regulatory hurdles, and substantial investment in research and development. The company's focus on rare and severe metabolic and kidney disorders positions it within a niche market with potentially less competition but also smaller patient populations. The biotechnology industry is driven by advancements in genomics, proteomics, and other areas of biological science, leading to the development of novel therapies for previously untreatable diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying for market share in various therapeutic areas.
Key Customers
- Patients with hyperuricemia and gout
- Patients with advanced chronic kidney disease
- Healthcare providers treating these patients
- Pharmacies dispensing the medication
Financials
Chart & Info
Allena Pharmaceuticals, Inc. (ALNA) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Apr 26, 2022
-
Stocks That Hit 52-Week Lows On Friday
· Nov 8, 2019
-
Stocks That Hit 52-Week Lows On Wednesday
· Oct 2, 2019
-
Stocks That Fell Through 52-Week Lows Wednesday
· Aug 7, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALNA.
Price Targets
Wall Street price target analysis for ALNA.
MoonshotScore
What does this score mean?
The MoonshotScore rates ALNA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Louis Brenner
CEO
Louis Brenner serves as the Chief Executive Officer of Allena Pharmaceuticals, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on corporate strategy, business development, and commercialization. Prior to joining Allena, he held leadership positions at various biotechnology and pharmaceutical companies, where he was responsible for driving growth and innovation. He has a strong track record of building and managing successful teams, as well as executing strategic transactions.
Track Record: Under Louis Brenner's leadership, Allena Pharmaceuticals, Inc. has focused on advancing the clinical development of ALLN-346 and exploring strategic opportunities to expand its pipeline. Key milestones include initiating and completing clinical trials for ALLN-346 and securing funding to support the company's research and development efforts. He is managing 12 employees.
Common Questions About ALNA
What does Allena Pharmaceuticals, Inc. do?
Allena Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing oral enzyme therapeutics for patients with rare and severe metabolic and kidney disorders. Their lead product candidate, ALLN-346, is designed to treat hyperuricemia and gout in patients with advanced chronic kidney disease by degrading urate in the gastrointestinal tract. The company aims to provide convenient and effective treatment options for these debilitating conditions, addressing significant unmet medical needs.
What do analysts say about ALNA stock?
AI analysis is pending for Allena Pharmaceuticals, Inc. Therefore, a summary of analyst consensus, key valuation metrics, and growth considerations is currently unavailable. Investors should conduct their own due diligence and consult with financial professionals before making any investment decisions. Further information will be provided once the AI analysis is complete.
What are the main risks for ALNA?
Allena Pharmaceuticals, Inc. faces several risks inherent to the biotechnology industry. These include the potential for clinical trial failures, regulatory hurdles in obtaining approval for ALLN-346, and competition from existing and emerging therapies. The company's limited financial resources and dependence on a single product candidate also pose significant risks. Patent expiration and the emergence of biosimilars could also impact future revenue streams.
What are the key growth opportunities for ALNA in healthcare?
Allena Pharmaceuticals, Inc. can explore expansion into new therapeutic areas, leveraging its expertise in enzyme therapeutics to address other metabolic and kidney disorders. Geographic expansion into international markets with significant patient populations also presents a growth opportunity. Strategic partnerships and collaborations with larger pharmaceutical companies can provide access to additional resources and expertise. The development of next-generation enzyme therapeutics with improved efficacy and delivery methods is another avenue for growth.
How does Allena Pharmaceuticals, Inc. manage patent expiration risks?
As ALLN-346 progresses through clinical trials and towards potential commercialization, Allena Pharmaceuticals, Inc. will need to proactively manage patent expiration risks. This involves continually innovating and developing new enzyme therapeutics or formulations to extend patent protection. The company can also pursue strategic partnerships and licensing agreements to diversify its product pipeline and reduce reliance on a single product. Effective lifecycle management strategies are crucial to mitigating the impact of patent expiration and maintaining a competitive advantage.
What are the key factors to evaluate for ALNA?
Evaluating ALNA involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Proprietary enzyme technology platform. Primary risk to monitor: Potential: Clinical trial failures.. This is not financial advice.
How frequently does ALNA data refresh on this page?
ALNA prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ALNA's recent stock price performance?
Recent price movement in Allena Pharmaceuticals, Inc. (ALNA) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary enzyme technology platform. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-17.
- AI analysis is pending, which may provide further insights.